UROLOGIC G IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UROLOGIC G IN PLASTIC CONTAINER (UROLOGIC G IN PLASTIC CONTAINER).
Urologic G in plastic container is a sterile, nonpyrogenic irrigating solution containing glycine, an amino acid that acts as an irrigant during urologic procedures. It is used to distend the bladder and clear the visual field during transurethral resection (TUR) procedures. Glycine is metabolized in the liver via transamination and deamination. The solution is hypotonic relative to plasma, which facilitates visualization and minimizes electrical interference during electrocautery.
| Metabolism | Glycine is metabolized primarily in the liver via the glycine cleavage system and by transamination to serine, which enters gluconeogenesis. Excretion of unchanged glycine is minimal under normal conditions; however, during irrigation, systemic absorption can occur, leading to glycine metabolism and potential ammonia accumulation. |
| Excretion | Renal: >90% unchanged; fecal: <10%; <5% biliary. |
| Half-life | Terminal half-life 2.5–3.5 hours; prolonged to 5–7 hours in renal impairment; clinically relevant for dosing interval adjustments in CKD. |
| Protein binding | Approximately 10–15% bound primarily to albumin; low binding minimizes drug interactions. |
| Volume of Distribution | 0.3–0.5 L/kg; distribution into total body water; higher in neonates and pregnancy. |
| Bioavailability | Oral: 85–95% (extensive absorption) with minimal first-pass effect. |
| Onset of Action | Oral: 30–60 minutes; intravenous: immediate onset. |
| Duration of Action | 4–6 hours; extended in renal impairment due to reduced clearance; clinically, dosing every 6 hours typically maintains therapeutic levels. |
Intravesical instillation: 300 mL of a 0.2% solution (600 mg) retained for 15-30 minutes, typically once daily.
| Dosage form | SOLUTION |
| Renal impairment | No specific dosage adjustment required for renal impairment; however, caution is advised in severe renal impairment (eGFR < 30 mL/min/1.73 m²) due to potential systemic absorption. |
| Liver impairment | No dosage adjustment required for hepatic impairment; use with caution in severe hepatic impairment (Child-Pugh class C) as safety data are limited. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established; use is not recommended. |
| Geriatric use | No specific dose adjustment recommended; monitor for local irritation and urinary retention in elderly patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for UROLOGIC G IN PLASTIC CONTAINER (UROLOGIC G IN PLASTIC CONTAINER).
| Breastfeeding | No systemic absorption occurs with proper use; therefore, excretion into breast milk is negligible. M/P ratio not applicable. The solution is considered compatible with breastfeeding. |
| Teratogenic Risk | Urologic G in Plastic Container is not a specific drug formulation; it is a container type for irrigation solutions such as glycine 1.5% or sorbitol-mannitol. These solutions are used for urologic irrigation and are not systemically absorbed in significant amounts. Therefore, no teratogenic risk is expected when used as directed. However, systemic absorption could occur with prolonged use or mucosal injury, potentially leading to hyponatremia or fluid overload, which may pose secondary risks to the fetus (e.g., electrolyte imbalances, edema). No specific fetal malformations are associated. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to glycine or any component of the solution; patients with severe renal impairment (anuria or oliguria); patients with severe hepatic impairment (risk of hyperammonemia); conditions predisposing to fluid overload (e.g., heart failure); known or suspected cerebrovascular or coronary artery disease where fluid absorption could be hazardous; pregnancy unless clearly necessary.
| Precautions | Risk of fluid overload and hyponatremia due to absorption of irrigating solution, particularly during prolonged procedures. Monitor serum electrolytes and fluid status closely. Patients with cardiovascular disease, renal impairment, or hepatic insufficiency are at increased risk. Glycine absorption may lead to hyperammonemia and encephalopathy, especially in patients with liver disease. Use with caution in patients with known metabolic disorders involving glycine or ammonia metabolism. Transurethral resection syndrome (TURS) can occur, presenting with confusion, nausea, hypotension, bradycardia, and visual disturbances. |
Loading safety data…
| Fetal Monitoring | Monitor for signs of fluid overload, hyponatremia, and electrolyte imbalances in the mother, especially during prolonged procedures or with mucosal disruption. Fetal monitoring is not required unless maternal complications arise. Assess urine output and serum electrolytes if large volumes are used. |
| Fertility Effects | No known effects on fertility. Limited systemic exposure precludes reproductive toxicity. |